News >

Greater Genomic Understanding Is Gateway to Drug Development in TNBC

Caroline Seymour
Published: Monday, Dec 31, 2018

Roberto A. Leon Ferre, MD

Roberto A. Leon Ferre, MD
The use of PARP inhibitors, antibody-drug conjugates, and immunotherapies have all shown significant activity in select subgroups of patients with triple-negative breast cancer (TNBC), but greater insight into the genomics and proteomics responsible for driving tumor growth are needed to inform development of novel therapeutics, explained Roberto A. Leon Ferre, MD.

 
Regarding driver mutations, patients who harbor aberrations amenable to the available targeted therapies account for a small percentage of the TNBC population, said Leon Ferre, with cytotoxic chemotherapy remaining the predominant therapeutic approach for the 60% to 70% of patients who do not express a specific target.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Community Practice Connections™: Evolving Applications for PARP Inhibitors in Ovarian Cancer: Building on a Solid FoundationAug 15, 20191.5
Publication Bottom Border
Border Publication
x